Autonomix Medical Expands U.S. Patent Protection for Neuromodulation

THE WOODLANDS, Texas, Aug. 26, 2026

New Patent Strengthens Feedback-Guided Treatment Technology

Autonomix Medical’s newly issued patent describes medical systems incorporating a surgical instrument with one or more therapeutic delivery elements and a controller capable of adjusting treatment based on physiological information obtained from the targeted tissue region. A key aspect of the patent is the ability to control the quantity and delivery of therapeutic fluid according to its distribution within targeted tissue, potentially allowing treatment delivery to be adjusted based on real-time feedback. The patent also encompasses systems integrating imaging and sensing capabilities, creating a framework for more controlled intervention. Importantly, the protected applications include scenarios where the targeted tissue comprises a tumor and the delivered therapeutic fluid is configured to produce neural ablation to reduce cancer pain. The patent additionally covers denervating agents, sympathetic and parasympathetic nerve-specific denervating agents and neuroblocking agents. This intellectual property expands the scope of Autonomix Medical’s existing technology platform as the company continues developing precision approaches for nerve-targeted interventions.

Platform Combines Sensing, Imaging and Targeted Therapy

The patent further describes systems and methods for monitoring, imaging, stimulating and ablating neurological structures associated with organs of the lower urinary tract, while outlining broader applications involving organ function, hormone secretion and organ or tumor growth. The technology is designed to support minimally invasive access to neural structures, including approaches through arteries and veins, with physiological and electrophysiological feedback used to guide and evaluate treatment. According to Autonomix Medical, the newly issued patent strengthens its intellectual property position around precisely controlled, feedback-guided intervention of targeted tissue and neural structures. The patent is based on a continuation application tracing back to patent applications filed in 2012 and 2014, highlighting the longstanding development of the underlying technology. The expanded patent coverage provides additional protection as the company explores applications of its platform across neuromodulation and targeted ablation.

Autonomix Medical Advances Precision Nerve-Targeted Treatments

Autonomix Medical is developing a platform technology focused on diagnosing and treating diseases involving the nervous system. Its core technology incorporates a catheter-based microchip sensing array designed to detect and differentiate neural signals with potentially greater sensitivity than currently available technologies. The company is initially developing the platform for pain treatment, with clinical development focused on pancreatic cancer, where cancer-associated pain can be debilitating and difficult to manage. Beyond oncology pain, Autonomix Medical identifies potential applications across a broader range of conditions, including cardiology, hypertension and chronic pain management. The company believes its technology could ultimately support transvascular diagnosis and treatment of peripheral nervous system conditions in different parts of the body. The platform remains investigational and has not been cleared for marketing in the United States. The newly issued U.S. patent therefore represents an intellectual property milestone, rather than a regulatory approval or demonstration of clinical efficacy.

Source: Autonomix Medica press relese